Business
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
TWYNEO will be officially launched for commercial availability in Spring 2022. NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies,
About this update from Sol-gel Technologies Ltd.
[{"type":"text","content":"TWYNEO will be officially launched for commercial availability in Spring 2022.\nNESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that its U.S. commercialization partner, Galderma, will be promoting TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts. TWYNEO Cream is the first and only tretinoin and benzoyl peroxide 2-in-1 combination proven to treat moderate-to-severe acne.1,2 Patented microencapsulation technology unites two ingredients that previously could never be combined and enables their slow release to deliver visible results in as little as two weeks.2-4 Sol-Gel’s partner Galderma will make a presentation on TWYNEO during its series of speaker forum talks. Information on this presentation is below: Groundbreaking Acne Treatment: TWYNEO Cream: Dermatology’s Only Combination .1% Tretinoin and 3% BPO for Moderate to Severe Acne VulgarisOmar Noor, MD, FAADSaturday, March 26 12:30-12:55 pm ETGalderma booth #1117 In addition, TWYNEO will be featured in one of Galderma’s four product theatres set up with the purpose discuss to new research findings as part of their product portfolio: Acne: TWYNEO & AKLIEF® Hilary Baldwin, MD, FAADFriday, March 25 10:30 – 11:15 am ETTheater 2 Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel Technologies, commented, “We are very pleased that our first approved product that is based on our proprietary microencapsulation technology, TWYNEO, will be showcased at a key medical dermatology meeting by our U.S. commercialization partner, Galderma. The high degree of visibility afforded to TWYNEO by the Galderma team is a testament to their commitment to optimize the commercial opportunities for this drug as well as to communicate its benefits as the first-ever tretinoin and benzoyl peroxide combination that can be used to treat even moderate-to-severe cases of acne.” About Acne Vulgaris Acne vulgaris is a common multifactorial skin disease that according to the American Academy of Dermatology affects up to 50 million people in the U.S. The disease occurs most frequently dur...